114 related articles for article (PubMed ID: 23138529)
41. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas.
Aghajanian C; Burris HA; Jones S; Spriggs DR; Cohen MB; Peck R; Sabbatini P; Hensley ML; Greco FA; Dupont J; O'Connor OA
J Clin Oncol; 2007 Mar; 25(9):1082-8. PubMed ID: 17261851
[TBL] [Abstract][Full Text] [Related]
42. First clinical pharmacokinetic dose-escalation study of sagopilone, a novel, fully synthetic epothilone, in Japanese patients with refractory solid tumors.
Araki K; Kitagawa K; Mukai H; Mukohara T; Kodama K; Ando Y; Narabayashi M; Minami H; Mera K; Sasaki Y
Invest New Drugs; 2012 Dec; 30(6):2327-33. PubMed ID: 22139065
[TBL] [Abstract][Full Text] [Related]
43. A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors.
Sasaki Y; Miwa K; Yamashita K; Sunakawa Y; Shimada K; Ishida H; Hasegawa K; Fujiwara K; Kodaira M; Fujiwara Y; Namiki M; Matsuda M; Takeuchi Y; Katsumata N
Invest New Drugs; 2015 Apr; 33(2):332-40. PubMed ID: 25380636
[TBL] [Abstract][Full Text] [Related]
44. Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors.
Mizugaki H; Yamamoto N; Murakami H; Kenmotsu H; Fujiwara Y; Ishida Y; Kawakami T; Takahashi T
Invest New Drugs; 2016 Oct; 34(5):596-603. PubMed ID: 27363843
[TBL] [Abstract][Full Text] [Related]
45. Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors.
Shitara K; Yamazaki K; Tsushima T; Naito T; Matsubara N; Watanabe M; Sarholz B; Johne A; Doi T
Jpn J Clin Oncol; 2020 Aug; 50(8):859-866. PubMed ID: 32328660
[TBL] [Abstract][Full Text] [Related]
46. Phase I study of larotaxel administered as a 1-h intravenous infusion every 3 weeks to Japanese patients with advanced solid tumours.
Yamamoto N; Boku N; Minami H
Cancer Chemother Pharmacol; 2009 Dec; 65(1):129-36. PubMed ID: 19437020
[TBL] [Abstract][Full Text] [Related]
47. Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors.
Nakamichi S; Nokihara H; Yamamoto N; Yamada Y; Fujiwara Y; Tamura Y; Wakui H; Honda K; Mizugaki H; Kitazono S; Tanabe Y; Asahina H; Yamazaki N; Suzuki S; Matsuoka M; Ogita Y; Tamura T
Invest New Drugs; 2015 Jun; 33(3):641-51. PubMed ID: 25809858
[TBL] [Abstract][Full Text] [Related]
48. Targeting survivin with YM155 (Sepantronium Bromide): a novel therapeutic strategy for paediatric acute myeloid leukaemia.
Smith AM; Little EB; Zivanovic A; Hong P; Liu AK; Burow R; Stinson C; Hallahan AR; Moore AS
Leuk Res; 2015 Apr; 39(4):435-44. PubMed ID: 25659731
[TBL] [Abstract][Full Text] [Related]
49. Quinone-Based Antitumor Agent Sepantronium Bromide (YM155) Causes Oxygen-Independent Redox-Activated Oxidative DNA Damage.
Wani TH; Surendran S; Jana A; Chakrabarty A; Chowdhury G
Chem Res Toxicol; 2018 Jul; 31(7):612-618. PubMed ID: 29897742
[TBL] [Abstract][Full Text] [Related]
50. Population pharmacokinetics and pharmacokinetics/pharmacodynamics of bendamustine in pediatric patients with relapsed/refractory acute leukemia.
Darwish M; Megason G; Bond M; Hellriegel E; Robertson P; Grasela T; Phillips L
Curr Med Res Opin; 2014 Nov; 30(11):2305-15. PubMed ID: 25105914
[TBL] [Abstract][Full Text] [Related]
51. Therapeutic potential of sepantronium bromide YM155 in gemcitabine-resistant human urothelial carcinoma cells.
Huang YT; Cheng CC; Lin TC; Chiu TH; Lai PC
Oncol Rep; 2014 Feb; 31(2):771-80. PubMed ID: 24297644
[TBL] [Abstract][Full Text] [Related]
52. Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer.
Yamamoto N; Fujiwara Y; Tamura K; Kondo S; Iwasa S; Tanabe Y; Horiike A; Yanagitani N; Kitazono S; Inatani M; Tanaka J; Nishio M
Invest New Drugs; 2017 Feb; 35(1):37-46. PubMed ID: 27565810
[TBL] [Abstract][Full Text] [Related]
53. Opicapone pharmacokinetics and pharmacodynamics comparison between healthy Japanese and matched white subjects.
Falcão A; Rocha JF; Santos A; Nunes T; Soares-da-Silva P
Clin Pharmacol Drug Dev; 2016 Mar; 5(2):150-61. PubMed ID: 27138028
[TBL] [Abstract][Full Text] [Related]
54. Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
Guo F; Letrent SP; Munster PN; Britten CD; Gelmon K; Tolcher AW; Sharma A
Cancer Chemother Pharmacol; 2008 Jun; 62(1):97-109. PubMed ID: 17805538
[TBL] [Abstract][Full Text] [Related]
55. Synergistic antitumor activities of sepantronium bromide (YM155), a survivin suppressant, in combination with microtubule-targeting agents in triple-negative breast cancer cells.
Kaneko N; Yamanaka K; Kita A; Tabata K; Akabane T; Mori M
Biol Pharm Bull; 2013; 36(12):1921-7. PubMed ID: 24432379
[TBL] [Abstract][Full Text] [Related]
56. Axitinib plasma pharmacokinetics and ethnic differences.
Chen Y; Suzuki A; Tortorici MA; Garrett M; LaBadie RR; Umeyama Y; Pithavala YK
Invest New Drugs; 2015 Apr; 33(2):521-32. PubMed ID: 25663295
[TBL] [Abstract][Full Text] [Related]
57. Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors.
Doi T; Ohtsu A; Fuse N; Yoshino T; Tahara M; Shibayama K; Takubo T; Weinreich DM
Cancer Chemother Pharmacol; 2013 Jan; 71(1):227-35. PubMed ID: 23124648
[TBL] [Abstract][Full Text] [Related]
58. A randomized, single-blind, single-dose study to assess the pharmacokinetic equivalence of the biosimilar ABP 215 and bevacizumab in healthy Japanese male subjects.
Hanes V; Chow V; Pan Z; Markus R
Cancer Chemother Pharmacol; 2018 Nov; 82(5):899-905. PubMed ID: 30269275
[TBL] [Abstract][Full Text] [Related]
59. Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer.
Schöffski P; Thate B; Beutel G; Bolte O; Otto D; Hofmann M; Ganser A; Jenner A; Cheverton P; Wanders J; Oguma T; Atsumi R; Satomi M
Ann Oncol; 2004 Apr; 15(4):671-9. PubMed ID: 15033678
[TBL] [Abstract][Full Text] [Related]
60. A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokinetics.
Casulo C; Vose JM; Ho WY; Kahl B; Brunvand M; Goy A; Kasamon Y; Cheson B; Friedberg JW
Clin Immunol; 2014 Sep; 154(1):37-46. PubMed ID: 24928323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
